A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study

被引：0
作者：
Patrizia Vici
Giuseppe Colucci
Francesco Giotta
Domenico Sergi
Gianfranco Filippelli
Pasquale Perri
Claudio Botti
Enrico Vizza
Armando Carpino
Laura Pizzuti
Agnese Latorre
Diana Giannarelli
Massimo Lopez
Luigi Di Lauro
机构：
[1] Regina Elena National Cancer Institute,Division of Medical Oncology B
[2] Oncologic Institute,Department of Medical and Experimental Oncology
[3] Division of Medical Oncology,Division of Surgery A
[4] S. Francesco Hospital,Division of Gynecological Oncology
[5] Regina Elena National Cancer Institute,Cardiologic Unit
[6] Regina Elena National Cancer Institute,Biostatistics Unit
[7] Regina Elena National Cancer Institute,undefined
[8] Regina Elena National Cancer Institute,undefined
来源：
Journal of Experimental & Clinical Cancer Research | / 30卷
关键词：
Anthracyclines; Lapatinib; Pegylated Liposomal Doxorubicin; Neutropenic Fever; Advanced Breast Cancer Patient;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 49 条
  • [41] Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: Results from a multi-center phase II study of the NOGGO.
    Oskay-Oezcelik, Guelten
    Koensgen, Dominique
    Hindenburg, Hans-Joachim
    Klare, Peter
    Schmalfeldt, Barbara
    Lichtenegger, Werner
    Chekerov, Radoslav
    Al-Batran, Salah-Eddin
    Neumann, Ulf
    Sehouli, Jalid
    ANTICANCER RESEARCH, 2008, 28 (2B) : 1329 - 1334
  • [42] Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer
    Iqbal, S.
    Goldman, B.
    Fenoglio-Preiser, C. M.
    Lenz, H. J.
    Zhang, W.
    Danenberg, K. D.
    Shibata, S. I.
    Blanke, C. D.
    ANNALS OF ONCOLOGY, 2011, 22 (12) : 2610 - 2615
  • [43] Outcomes of re-treatment with first-line Trastuzumab plus a taxane in HER2 positive metastatic breast cancer patients after (neo)adjuvant Trastuzumab: A prospective multicenter study
    Xu, Binghe
    Hu, Xichun
    Zheng, Hong
    Wang, Xiaojia
    Zhang, Qingyuan
    Cui, Shude
    Liu, Donggeng
    Liao, Ning
    Luo, Rongcheng
    Sun, Qiang
    Yu, Shiying
    ONCOTARGET, 2016, 7 (31) : 50643 - 50655
  • [44] MM-SZ01 Study: A Prospective, Randomized, Controlled, Multicenter Phase III Clinical Study Which Compared Polyethylene Glycol Liposomal Doxorubicin Versus Doxorubicin Combined with Bortezomib and Dexamethasone (PDD regimen vs PAD regimen) in the Treatment of Newly Diagnosed Multiple Myeloma in China
    Wang, Qingqing
    Wu, Depei
    Fu, Chengcheng
    Yan, Shuang
    Jin, ChengHao
    Lu, Xuzhang
    Chen, Tao
    Li, Fei
    Xia, Zhongjun
    Li, Bingzhong
    BLOOD, 2022, 140 : 12614 - 12615
  • [45] Lapatinib with ECF/X in the first-line treatment of metastatic gastric cancer according to HER2neu and EGFR status: a randomized placebo-controlled phase II study (EORTC 40071)
    Moehler, Markus
    Schad, Arno
    Maderer, Annett
    Atasoy, Ajlan
    Mauer, Murielle E.
    Caballero, Carmela
    Thomaidis, Thomas
    John, Jestinah M. Mahachie
    Lang, Istvan
    Van Cutsem, Eric
    Freire, Joao
    Lutz, Manfred P.
    Roth, Arnaud
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (04) : 733 - 739
  • [46] Lapatinib with ECF/X in the first-line treatment of metastatic gastric cancer according to HER2neu and EGFR status: a randomized placebo-controlled phase II study (EORTC 40071)
    Markus Moehler
    Arno Schad
    Annett Maderer
    Ajlan Atasoy
    Murielle E. Mauer
    Carmela Caballero
    Thomas Thomaidis
    Jestinah M. Mahachie John
    Istvan Lang
    Eric Van Cutsem
    João Freire
    Manfred P. Lutz
    Arnaud Roth
    Cancer Chemotherapy and Pharmacology, 2018, 82 : 733 - 739
  • [47] Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial
    Hurvitz, Sara A.
    Andre, Fabrice
    Jiang, Zefei
    Shao, Zhimin
    Mano, Max S.
    Neciosup, Silvia P.
    Tseng, Ling-Min
    Zhang, Qingyuan
    Shen, Kunwei
    Liu, Donggeng
    Dreosti, Lydia M.
    Burris, Howard A.
    Toi, Masakazu
    Buyse, Marc E.
    Cabaribere, David
    Lindsay, Mary-Ann
    Rao, Shantha
    Pacaud, Lida Bubuteishvili
    Taran, Tetiana
    Slamon, Dennis
    LANCET ONCOLOGY, 2015, 16 (07) : 816 - 829
  • [48] Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer
    Perez, Edith A.
    Hurvitz, Sara A.
    Amler, Lukas C.
    Mundt, Kirsten E.
    Ng, Vivian
    Guardino, Ellie
    Gianni, Luca
    BREAST CANCER RESEARCH, 2014, 16 (03):
  • [49] Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer
    Edith A Perez
    Sara A Hurvitz
    Lukas C Amler
    Kirsten E Mundt
    Vivian Ng
    Ellie Guardino
    Luca Gianni
    Breast Cancer Research, 16
12345